Intensity Therapeutics schedules Q2 financial results conference callPUBT·Aug 4 at 07:07 AMINTS-212.00%
Life Beyond the Megacaps: The Complex Reality of 2026's Market MisfitsGlobal Report·Jul 24 at 04:13 AMYI+330.00%TLN+278.00%
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | INTS Stock NewsStockTitan·Jul 14 at 10:45 PMINTS-212.00%
PayPal's Crypto Pivot and Meta's Chip Push: Inside the Payments ReshuffleGlobal Report·Jul 9 at 09:02 PMPAYP-32.00%XNET+119.00%
US Small-Cap Capital Deployment Accelerates Amid Tech and Biotech PivotsGlobal Report·Jul 9 at 05:02 AMSTI+495.00%DWSN-900.00%
Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trialPUBT·Jul 1 at 07:04 AMINTS-212.00%
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation | INTS Stock NewsStockTitan·Apr 15 at 12:15 AMINTS-212.00%FBT+310.00%
